I don't see it that way at all. I believe that Haynes et al has done the research,
using Gates Foundation money, to figure out the MOA of the anti-lipid
antibodies in HIV infection. Duke may get the patent for how this MOA can
be used in a microbiocide, but Peregrine still has the antibodies and so would
get some sort of royalty. It might be possible that Gates would pay for a
clinical trial of the microbiocide in Africa. The pay off for Peregrine would be
a huge validation of their anti-phospholipid approach, and publicity, but this would
be years away. By then Bavi should be approved for a cancer indication.